Clinical Trial Update: Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating pembrolizumab with doxorubicin in metastatic or unresectable sarcoma; study completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sarcoma

Drugs mentioned

• DOXORUBICIN HYDROCHLORIDE (Doxorubicin hydrochloride)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Sarcoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-05-26